Hot Pursuit     06-May-24
Dr Reddy's Labs launches generic Oracea capsules in US markets
Dr Reddy's Laboratories said that it has launched Doxycycline Capsules in the U.S. market, which is a therapeutic generic equivalent of ORACEA Capsules of Galderma Laboratories.

Oracea is a tetracycline antibiotic. It is used to treat blemishes, bumps, and acne-like lesions caused by rosacea in adults. It works by reducing skin inflammation caused by rosacea.

Doxycycline capsules had estimated annual sales of USD 128 million in the US (IQVIA MAT February 2024).

Dr Reddy's Laboratories is engaged in providing medicines. The firm operates in three segments: global generics, pharmaceutical services and active ingredients (PSAI) and proprietary products.

The drug major's consolidated net profit increased 10.57% to Rs 1,378.9 crore on 6.57% rise in revenues to Rs 7,214.8 crore in Q3 FY24 over Q3 FY23.

The scrip fell 0.42% to currently trade at Rs 6323.15 on the BSE.

Previous News
  Dr Reddy’s Lab Andhra Pradesh facility gets 2 USFDA observations
 ( Hot Pursuit - 18-May-24   08:33 )
  Dr Reddys Laboratories
 ( Results - Analysis 08-May-24   09:36 )
  Dr Reddy's Q4 PAT jumps 36% YoY to Rs 1,307 crore
 ( Hot Pursuit - 07-May-24   17:26 )
  Dr Reddy's Laboratories consolidated net profit rises 36.42% in the March 2024 quarter
 ( Results - Announcements 07-May-24   16:59 )
  Dr Reddys Laboratories AGM scheduled
 ( Corporate News - 07-May-24   16:41 )
  Board of Dr Reddys Laboratories recommends final dividend
 ( Corporate News - 07-May-24   16:41 )
  Dr Reddy's Labs launches generic Oracea capsules in US markets
 ( Hot Pursuit - 06-May-24   09:29 )
  Dr Reddy's launches Doxycycline Capsules in the US
 ( Corporate News - 03-May-24   15:50 )
  Nestle India and Dr Reddy's to form JV focused on nutritional health solutions
 ( Corporate News - 25-Apr-24   12:56 )
  Dr. Reddy's launches condition management programme DailyBloom™ IBS
 ( Corporate News - 19-Apr-24   16:08 )
  Market at day's low; Nifty slides below 22,600
 ( Market Commentary - Mid-Session 12-Apr-24   13:31 )
Other Stories
  Kirloskar Ferrous Q4 PAT drops 81% YoY to Rs 18 cr
  18-May-24   16:00
  ZEEL reports turnaround Q4 numbers
  18-May-24   15:46
  NHPC Q4 PAT slides 18% to Rs 610 cr
  18-May-24   15:20
  Nestle India ends higher after public shareholders reject royalty hike proposal to Swiss parent
  18-May-24   15:12
  Sobha Q4 PAT drops 85% YoY to Rs 7 cr
  18-May-24   15:05
  Kirloskar Ferrous Industries Ltd leads losers in 'A' group
  18-May-24   15:00
  Vindhya Telelinks Ltd leads losers in 'B' group
  18-May-24   14:45
  Volumes soar at MTAR Technologies Ltd counter
  18-May-24   14:30
  Ashok Leyland Ltd up for third consecutive session
  18-May-24   13:05
  Zee Entertainment Enterprises Ltd spurts 4.37%
  18-May-24   13:05
Back Top